Boyce Sarah 4
4 · Avidity Biosciences, Inc. · Filed Jan 9, 2026
Insider Transaction Report
Form 4
Boyce Sarah
DirectorPresident and CEO
Transactions
- Sale
Common Stock
2026-01-07$72.23/sh−8,576$619,444→ 283,394 total
Footnotes (1)
- [F1]Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs on January 6, 2026 and the sale of the resulting shares of common stock on January 7, 2026. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary trade by the Reporting Person. The Reporting Person has executed an instruction letter for the automatic sale of such "sell-to-cover" shares, intended to satisfy the affirmative defense conditions of Rule 10b5-1.